| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥364.9B | ¥296.2B | +23.2% |
| Operating Income | ¥77.7B | ¥56.6B | +37.1% |
| Profit Before Tax | ¥73.1B | ¥55.3B | +32.1% |
| Net Income | ¥48.2B | ¥38.9B | +23.8% |
| ROE | 5.8% | 5.0% | - |
FY2026 Q3 cumulative results: Revenue 364.9B yen (YoY +23.2%), Operating Income 77.7B yen (+37.1%), Ordinary Income 73.1B yen (+32.3%), Net Income 48.2B yen (+23.8%). The company achieved strong double-digit growth across all profit levels, with operating income growing faster than revenue, indicating effective operating leverage. Gross profit margin maintained at a high 54.8% level, while operating margin reached 21.3%. Operating cash flow of 56.0B yen exceeded net income (OCF/NI ratio 1.16x), demonstrating solid cash-backed earnings quality. Total assets increased to 1,561.8B yen with equity ratio at 52.4%, maintaining stable capital structure. Q3 standalone quarter showed revenue of 134.1B yen (+21% QoQ) and EBITDA of 41.6B yen (+32% QoQ), confirming return to robust growth trajectory after Q2 deceleration.
Revenue growth of +23.2% YoY was primarily driven by the Health Big Data segment expansion (+26% YoY), particularly strong demand from pharmaceutical companies' sales and marketing domains (+30% YoY in data utilization transaction value, +43% YoY specifically in pharma sales/marketing). Medical provider-facing business also contributed significantly with +32% growth. The Telemedicine segment maintained steady growth at +5% YoY with high profitability. Operating income increased +37.1%, outpacing revenue growth due to improved operational efficiency and favorable business mix toward higher-margin services. The gross profit margin of 54.8% remained stable, while SG&A expenses grew at a slower rate than revenue, resulting in operating leverage effects. The gap between ordinary income (73.1B yen) and net income (48.2B yen) represents primarily corporate tax, with no material non-recurring items identified. This represents a "revenue up, profit up" pattern with accelerating profit growth, indicating strong business momentum and operational efficiency gains.
The Health Big Data segment is the core business, generating revenue of 316.3B yen (+26% YoY) and EBITDA of 85.8B yen (+32% YoY), with EBITDA margin of 27%. This segment accounted for approximately 87% of total revenue and was the primary driver of consolidated performance. Within this segment, Industry-facing data utilization grew +30% YoY, with pharmaceutical sales and marketing showing particularly strong growth at +43%. Medical provider-facing business expanded +32% YoY, while Insurer and Consumer-facing business grew +15% YoY, demonstrating balanced growth across all sub-segments. The Telemedicine segment contributed revenue of 48.6B yen (+5% YoY) and EBITDA of 18.4B yen (+6% YoY), maintaining exceptional profitability with EBITDA margin of 38%. Despite slower growth, this segment's high margin structure provides stable profit contribution. The core Health Big Data segment clearly drove both revenue and profit growth, with margin improvement from 26% to 27% YoY indicating successful execution of high-value-added service offerings and operational efficiency initiatives.
Profitability: ROE 5.8% (based on DuPont analysis: Net Margin 13.2% × Asset Turnover 0.234 × Financial Leverage 1.89), Operating Margin 21.3% (industry-leading level), EBITDA Margin 26.5%, Net Profit Margin 13.2%. Cash Quality: OCF/Net Income 1.16x (healthy cash generation), FCF -21.4B yen (negative due to large investments). Investment: Total investments in investing activities 77.4B yen including subsidiary acquisitions 63.1B yen, intangible asset acquisitions 10.5B yen, and property/plant/equipment 4.1B yen, indicating aggressive growth investment phase. Financial Health: Equity Ratio 52.4%, Interest-bearing Debt 426.4B yen, Net Debt/EBITDA approximately 1.3x (manageable level), Short-term Borrowings 55.9B yen (+27.2% YoY). Asset Efficiency: Total Asset Turnover 0.234 (low due to goodwill 634.4B yen representing 40.6% of total assets), Accounts Receivable 199.9B yen with DSO approximately 200 days (collection efficiency requires improvement).
Operating CF: 56.0B yen (1.16x of Net Income; cash-backed earnings confirmed). The positive spread over net income indicates high earnings quality, with working capital changes contributing favorably as accounts payable increased 42.9B yen. Investing CF: -77.4B yen, primarily consisting of subsidiary acquisitions 63.1B yen (strategic M&A execution), intangible asset acquisitions 10.5B yen (data platform and system investments), and property/plant/equipment 4.1B yen. These investments align with the strategic collaboration with electronic medical record providers announced in Q3 to build a dominant healthcare data infrastructure. Financing CF: -10.5B yen in dividend payments, +12.0B yen net increase in short-term borrowings. FCF: -21.4B yen (Operating CF 56.0B yen - CapEx approximated as tangible/intangible asset investments). Cash position: 302.4B yen in cash and equivalents provides adequate liquidity buffer. Cash generation: Operating cash generation is Strong, but overall liquidity Needs Monitoring due to aggressive investment posture and increasing short-term debt (cash/short-term liabilities ratio showing stress signals). The negative FCF is driven by strategic investments expected to generate future returns, though ROIC at 4.1% indicates returns have not yet fully materialized.
Ordinary vs Net Income: Ordinary income of 73.1B yen and net income of 48.2B yen show a difference of 24.9B yen (34.1% of ordinary income), primarily attributable to income tax expense with no material non-recurring items identified in the disclosed data. Non-operating income/expense impact is minimal relative to operating income, indicating earnings are driven predominantly by core business operations. Accruals: Operating CF of 56.0B yen exceeding Net Income of 48.2B yen (ratio 1.16x) demonstrates healthy accruals quality with no red flags. The positive accruals indicate working capital management is supporting cash generation, particularly through accounts payable increase. However, accounts receivable at 199.9B yen with DSO of approximately 200 days represents a significant working capital burden and collection risk that warrants monitoring. Overall earnings quality is assessed as High for current period, with strong cash backing and operating-driven profits, though the extended receivables collection period is a structural concern requiring improvement.
Full-year guidance: Revenue 505.0B yen, Operating Income 115.0B yen, Net Income 75.0B yen. Q3 cumulative progress rates: Revenue 72.3% (364.9B/505.0B), Operating Income 67.5% (77.7B/115.0B), Net Income 64.3% (48.2B/75.0B). Against standard quarterly progression (Q3 cumulative = 75%), revenue is tracking 2.7pt below, operating income is 7.5pt below, and net income is 10.7pt below standard pace. However, Q3 standalone quarter showed strong acceleration with revenue 134.1B yen and EBITDA 41.6B yen, representing sequential growth of +21% and +32% respectively from Q2. Management commentary indicates the business has returned to robust growth trajectory after Q2 deceleration, with strong momentum in pharmaceutical sales/marketing domain, recovering trends in medical domain and life insurance business, and steady expansion in insurer/consumer and medical provider domains. Given Q4 is typically the strongest quarter for the business and current momentum, full-year guidance achievement appears feasible, though operating income and net income will require Q4 acceleration to reach targets. Key factors for guidance achievement include: sustained pharmaceutical domain demand, medical domain order intake conversion, and continued operational efficiency gains.
Year-end dividend of 16.00 yen per share has been determined. Based on full-year EPS forecast of 113.2 yen, the implied full-year dividend payout ratio is approximately 14.1%. Using Q3 cumulative net income of 48.2B yen and EPS of 73.58 yen, the annualized payout ratio approximates 21.8%. Dividend sustainability is Strong given the conservative payout ratio and operating cash flow of 56.0B yen substantially covering the dividend payment of 10.5B yen (OCF coverage 5.4x). However, FCF is negative at -21.4B yen due to aggressive investment activities, resulting in FCF dividend coverage of -2.05x. The company maintains cash and equivalents of 302.4B yen, providing ample buffer for dividend continuation. No share buyback activity is disclosed in the current period. Total shareholder return policy is not explicitly stated, but the low payout ratio suggests room for future dividend growth as investments mature and FCF turns positive. Medium-term dividend sustainability depends on investment returns (ROIC improvement) and FCF recovery, though near-term risk is minimal given strong operating cash generation and cash reserves.
Near-term: (1) Q4 performance delivery toward full-year guidance achievement, particularly operating income and net income acceleration needed to close the gap to targets. (2) Pharmaceutical sales and marketing domain demand continuation, with strong order intake momentum expected to translate into revenue in Q4. (3) Medical domain business recovery materialization, as order intake has been increasing and is expected to contribute to growth. (4) Life insurance business recovery from H1 softness continuing into Q4.
Long-term: (1) Strategic collaboration with electronic medical record providers to build dominant medical institution-derived data infrastructure, with contribution expected from FY2027 onward. (2) Generative AI adoption acceleration driving increased demand for objective data in hypothesis validation cycles. (3) Healthcare tech industry consolidation presenting partnership opportunities with truly valuable players. (4) Expansion of high-value-added consulting and data/AI solutions to pharmaceutical sales and marketing departments. (5) New data utilization initiatives including elderly data for insurers creating additional revenue streams. (6) ROIC improvement from past M&A investments (634.4B yen goodwill) as synergies materialize.
Industry Position (Reference - Proprietary Analysis)
Profitability: Operating Margin 21.3% vs. industry median 8.0% (significantly above median, top quartile performance), Net Profit Margin 13.2% vs. industry median 5.6% (above median), ROE 5.8% vs. industry median 8.2% (below median due to low asset turnover), ROIC 4.1% vs. industry median 16.0% (significantly below median, indicating capital efficiency challenge).
Growth: Revenue Growth YoY 23.2% vs. industry median 10.5% (above median, strong growth), EPS Growth 23.8% vs. industry median 30.0% (in line with industry).
Financial Health: Equity Ratio 52.4% vs. industry median 59.5% (slightly below median but healthy), Current Ratio calculation not available vs. industry median 2.13x.
Efficiency: Asset Turnover 0.234 vs. industry median 0.68 (significantly below median due to goodwill-heavy balance sheet), Receivables Turnover Days approximately 200 vs. industry median 60.53 days (collection efficiency significantly lags industry), Operating Working Capital Turnover Days elevated vs. industry median 45.15 days.
Cash Flow: OCF/Net Income 1.16x vs. industry median 1.40x (healthy but slightly below median), FCF Yield negative vs. industry median 6.0% (investment phase).
Summary: The company demonstrates industry-leading profit margins reflecting high-value-added business model, but capital efficiency metrics (ROE, ROIC, asset turnover) lag industry medians due to goodwill-heavy balance sheet from M&A strategy and extended receivables collection. Revenue growth exceeds industry median, positioning the company as a growth leader in the IT/Telecom sector. Financial health is adequate though equity ratio is modestly below median.
Industry: IT and Telecom (99 companies), Comparison: FY2025 Q3 period, Source: Proprietary analysis
(1) Goodwill Impairment Risk: Goodwill of 634.4B yen represents 40.6% of total assets and 77.0% of equity. If acquired businesses fail to generate expected returns or market conditions deteriorate, material impairment losses could occur, significantly impacting earnings and equity. Current ROIC of 4.1% (vs. industry median 16.0%) suggests investment returns have not fully materialized, increasing impairment risk if performance does not improve.
(2) Accounts Receivable Collection Risk: Receivables of 199.9B yen with DSO approximately 200 days (vs. industry median 60.53 days) represents significant working capital burden and credit risk. Extended collection period constrains cash flow and increases exposure to customer credit events, particularly relevant given major customers include insurers, medical institutions, and pharmaceutical companies subject to regulatory and reimbursement changes. Quality alert flags indicate this as a material operational concern.
(3) Regulatory and Healthcare System Risk: Business model depends on healthcare data utilization under current regulatory framework. Changes in medical/insurance systems, data privacy regulations, pharmaceutical marketing regulations, or reimbursement policies could materially impact customer demand, data access rights, and business viability. The company operates in a highly regulated sector where policy shifts can rapidly alter market dynamics.
(1) High-Margin Growth Business with Capital Efficiency Challenge: The company demonstrates exceptional profit margins (Operating Margin 21.3% vs. industry median 8.0%, Net Margin 13.2% vs. 5.6%) and strong revenue growth (+23.2% vs. industry median +10.5%), confirming a differentiated, high-value-added business model in healthcare data analytics. However, ROE of 5.8% (vs. industry median 8.2%) and ROIC of 4.1% (vs. industry median 16.0%) indicate capital efficiency significantly lags industry, primarily due to goodwill-heavy balance sheet (634.4B yen) and low asset turnover (0.234 vs. median 0.68). The key observation is that profitability from operations is strong, but M&A-driven growth strategy has not yet translated into commensurate returns on invested capital.
(2) Strong Cash Generation Offset by Aggressive Investment Posture: Operating cash flow of 56.0B yen exceeded net income (1.16x ratio), confirming high-quality cash-backed earnings from core operations. However, FCF is negative 21.4B yen due to 77.4B yen investing cash outflow including 63.1B yen subsidiary acquisition. This indicates the company is in active investment phase, prioritizing growth over near-term cash returns. The sustainability of this strategy depends on investment returns materializing—current ROIC of 4.1% suggests returns are delayed. With cash reserves of 302.4B yen and manageable debt (Net Debt/EBITDA approximately 1.3x), financial flexibility exists to continue investments, but efficiency improvement is critical for long-term value creation.
(3) Structural Working Capital Issue Requires Monitoring: Accounts receivable DSO of approximately 200 days (vs. industry median 60.53 days) represents a significant structural weakness in cash conversion cycle. While operating CF currently remains healthy, the extended collection period ties up substantial capital, increases credit risk exposure, and constrains financial flexibility. This is flagged in quality alerts and represents a material operational risk. Improvement in receivables collection efficiency would materially enhance cash generation capacity and reduce working capital burden. The trend and management actions on this metric are critical factors for assessing operational execution quality and cash flow sustainability.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
For the cumulative period through Q3 of FY March 2026, JMDC delivered solid results with consolidated revenue of 36,488 million yen (+23% YoY) and consolidated EBITDA of 9,682 million yen (+27% YoY). The core Health Big Data segment led high growth with revenue +26% and EBITDA +32%. Industry-facing data utilization grew +30% centered on sales and marketing for pharmaceutical companies, and healthcare provider-facing also performed well at +32%. The Telemedicine segment posted revenue +5% and EBITDA +6%, maintaining high profitability (EBITDA margin 38%). In Q3, the company recovered from the Q2 deceleration and returned to a robust growth trajectory. Management assessed progress as on track toward achieving full-year guidance, highlighting the proliferation of generative AI, expanding data demand, and strategic partnerships with electronic medical record (EMR) vendors as growth opportunities.
The Health Big Data segment achieved high growth with revenue +26% YoY and EBITDA +32%, with profitability also improving. Transaction value of data utilization in sales and marketing for pharmaceutical companies expanded strongly at +43% YoY. In Q3 standalone, consolidated revenue was 13,407 million yen (+21% QoQ) and EBITDA 4,157 million yen (+32% QoQ), making the recovery trend clear. Announced strategic partnerships with EMR vendors to accelerate the build-out of a dominant foundation of provider-derived data. Projecting that advancement in generative AI will accelerate the hypothesis-testing cycle and relatively increase demand for objective data.
Momentum across the business remains solid toward achieving full-year guidance. Robust demand persists in sales and marketing for pharmaceutical companies, sustaining strong growth. While progress in leveraging new senior (elderly) data in the Medical domain was delayed, recent bookings are trending upward with a re-acceleration expected. The life insurance business is recovering from softness in the first half, and growth momentum heading into the next fiscal year is steadily strengthening. For insurers and consumers, the data platform continues to expand steadily, and the healthcare provider-facing business is also growing well, centered on high value-added offerings.
Management characterized Q3 results as a “return to the company’s inherently strong growth trajectory.” Concerns about the sense of deceleration in Q2 were alleviated by re-acceleration in Q3. New data initiatives and efficiency gains in the Health Big Data segment contributed to profit growth outpacing revenue growth. The company reaffirmed its commitment to achieving full-year guidance. It views generative AI and consolidation within the health tech industry as positive opportunities and expressed expectations for outcomes from EMR integrations from next fiscal year onward.
Strengthen provider-derived data through strategic partnerships with EMR vendors to build an unparalleled data foundation. Leverage increased data demand accompanying the broader use of generative AI as a tailwind, supporting more advanced customer decision-making. Deploy high value-added consulting and data/AI solutions for sales and marketing divisions of pharmaceutical companies. Promote proposals for insurers utilizing new data such as senior (elderly) datasets to drive re-acceleration. Capitalize on consolidation trends in the health tech space by proactively partnering with truly value-accretive partners.
Delay in progress utilizing senior (elderly) data in the Medical division (bookings are trending up with recovery expected). Temporary deceleration observed in Q2 (recovered in Q3). Softness in the life insurance business in the first half (currently recovering). Privatizations and M&A-driven consolidation trends in health tech (assessed to have limited impact on the company’s performance). Acceleration of the hypothesis-testing cycle as generative AI advances, leading to a relative increase in demand for data-backed validation (both an opportunity and a risk).